ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2662

Effect of Tobacco Smoking on the Clinical, Histopathological, and Serological Manifestations of SjöGren’s Syndrome

Astrid Rasmussen1, Donald U. Stone2, Dustin Fife3, Michael Brown4, Keith Earley5, Lida Radfar6, C. Erick Kaufman7, David M. Lewis8, Nelson L. Rhodus9, Barbara M. Segal10, Daniel J Wallace11, Michael Weisman12, Swamy Venuturupalli13, Michael T. Brennan14, Christopher J Lessard3, Courtney G. Montgomery15, R. Hal Scofield15 and Kathy L. Sivils15, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, 2King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Pfizer Inc., Groton, CT, 559th Medical Wing, US Air Force, San Antonio, TX, 6Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, 7Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, 8Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, 9Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, 10Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, 11Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 12Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 13Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA, 14Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, 15Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: , , ,

Session Information

Date: Tuesday, November 15, 2016

Title: Sjögren's Syndrome - Poster II: Clinical Science

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess the prevalence of smoking in patients with Sjögren’s syndrome (SS) and non-Sjögren’s sicca (non-SS sicca), and the association of smoking habits with the clinical, serological, and histopathological manifestations of SS.

Methods: Cross-sectional case-control study of 1288 patients with sicca symptoms (587 SS and 701 non-SS sicca) evaluated in a multi-disciplinary research clinic. Smoking patterns were obtained from questionnaire data and disease-related clinical and laboratory data were compared between current, past, ever, and never smokers.

Results: Current smoking rates were 4.6% for SS patients compared to 14.1% in non-SS sicca (p=5.17x10E-09), 18% in a local lupus cohort (p=1.13x10E-14) and 16.8% in the community (p=4.12x10E-15). Current smoking was protective against SS classification (OR 0.35, 95%CI 0.22-0.56, FDR q=1.35E10-05), focus score ≥1 (OR 0.22, 95%CI 0.13-0.39, FDR q= 6.78x10E-08), and anti-Ro/SSA(+) (OR 0.35, 95%CI 0.2-0.63, FDR q=0.0009); ever smoking was protective against the same features and against anti-La/SSB(+) (OR 0.52, 95%CI 0.39-0.70, FDR q=0.001). Duration of smoking was inversely correlated with SS even after controlling for socioeconomic status, BMI, alcohol and caffeine consumption.

Conclusion: Current tobacco smoking is negatively and independently associated with SS, protecting against disease-associated humoral and cellular autoimmunity. The overall smoking rate amongst SS patients is significantly lower than in matched populations and the effects of smoking are proportional to exposure duration.In spite of the protective effects of tobacco on SS manifestations, it is associated with other serious comorbidities such as lung disease, cardiovascular risk and malignancy, and should thus be strongly discouraged in patients with sicca.

Disclosure: A. Rasmussen, None; D. U. Stone, None; D. Fife, None; M. Brown, None; K. Earley, None; L. Radfar, None; C. E. Kaufman, None; D. M. Lewis, None; N. L. Rhodus, None; B. M. Segal, None; D. J. Wallace, Exagen, 2; M. Weisman, None; S. Venuturupalli, None; M. T. Brennan, None; C. J. Lessard, None; C. G. Montgomery, None; R. H. Scofield, Eli Lilly and Company, 5,UCB, 5; K. L. Sivils, Eli Lilly and Company, 5,Medimmune, 5,Biogen, 5.

To cite this abstract in AMA style:

Rasmussen A, Stone DU, Fife D, Brown M, Earley K, Radfar L, Kaufman CE, Lewis DM, Rhodus NL, Segal BM, Wallace DJ, Weisman M, Venuturupalli S, Brennan MT, Lessard CJ, Montgomery CG, Scofield RH, Sivils KL. Effect of Tobacco Smoking on the Clinical, Histopathological, and Serological Manifestations of SjöGren’s Syndrome [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/effect-of-tobacco-smoking-on-the-clinical-histopathological-and-serological-manifestations-of-sjogrens-syndrome/. Accessed .

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-tobacco-smoking-on-the-clinical-histopathological-and-serological-manifestations-of-sjogrens-syndrome/